Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells)
- PMID: 2636801
- PMCID: PMC2589148
Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells)
Abstract
Induction of tolerance for skin allotransplantation requires selective suppression of the host response to foreign histocompatibility antigens. This report describes a new approach which employs pre-treatment with 8-methoxypsoralen (8-MOP) and ultraviolet A light (UVA) to render the effector cells of graft rejection immunogenic for the syngeneic recipient. Eight days after BALB/c mice received CBA/j skin grafts, their splenocytes were treated with 100 ng/ml 8-MOP and 1 J/cm2 UVA prior to reinfusion into naive BALB/c recipients. Recipient mice were tested for tolerance to alloantigens in mixed leukocyte culture (MLC), cytotoxicity (CTL), delayed-type hypersensitivity assays (DTH), and challenge with a fresh CBA/j graft. Splenocytes from BALB/c recipients of photoinactivated splenocytes containing the effector cells of CBA/j alloantigen rejection proliferated poorly in MLC and generated lower cytotoxic T-cell responses to CBA/j alloantigens in comparison with sensitized and naive controls and suppressed the MLC and CTL response to alloantigen from sensitized and naive BALB/c mice. In vivo, the DTH response was specifically suppressed to the relevant alloantigen in comparison with controls. BALB/c mice treated in this fashion retained a CBA/j skin graft for up to 42 days post-transplantation without visual evidence of rejection. These results showed that reinfusion of photoinactivated effector cells resulted in an immunosuppressive host response which specifically inhibited in vitro and in vivo responses that correlate with allograft rejection and permitted prolonged retention of histoincompatible skin grafts.
Similar articles
-
Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes.J Invest Dermatol. 1989 May;92(5):669-76. doi: 10.1111/1523-1747.ep12696853. J Invest Dermatol. 1989. PMID: 2523941
-
Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). Is in vivo cell transferrable?Ann N Y Acad Sci. 1991 Dec 30;636:95-112. doi: 10.1111/j.1749-6632.1991.tb33441.x. Ann N Y Acad Sci. 1991. PMID: 1793234
-
Inhibition of anti-skin allograft immunity induced by infusions with photoinactivated effector T lymphocytes--the congenic model.Transplantation. 1991 Jun;51(6):1283-9. doi: 10.1097/00007890-199106000-00026. Transplantation. 1991. PMID: 1828639
-
Cellular basis of allograft rejection.Immunol Rev. 1984;77:217-32. doi: 10.1111/j.1600-065x.1984.tb00723.x. Immunol Rev. 1984. PMID: 6370833 Review.
-
Experimental murine and primate models for dissection of the immunosuppressive potential of photochemotherapy in autoimmune disease and transplantation.Yale J Biol Med. 1989 Nov-Dec;62(6):611-20. Yale J Biol Med. 1989. PMID: 2700058 Free PMC article. Review.
Cited by
-
Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells.Blood. 2008 Aug 15;112(4):1515-21. doi: 10.1182/blood-2007-11-125542. Epub 2008 Apr 14. Blood. 2008. PMID: 18411417 Free PMC article.
-
Transplant Tolerance Induction: Insights From the Liver.Front Immunol. 2020 Jun 5;11:1044. doi: 10.3389/fimmu.2020.01044. eCollection 2020. Front Immunol. 2020. PMID: 32582167 Free PMC article. Review.
-
Cutaneous T-cell lymphoma: Biologic targets for therapy.Curr Hematol Malig Rep. 2007 Oct;2(4):272-7. doi: 10.1007/s11899-007-0037-8. Curr Hematol Malig Rep. 2007. PMID: 20425380 Review.
-
Harnessing the immune system in the treatment of cutaneous T cell lymphomas.Front Oncol. 2023 Jan 12;12:1071171. doi: 10.3389/fonc.2022.1071171. eCollection 2022. Front Oncol. 2023. PMID: 36713518 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources